PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 6, 2026Headache The Journal of Head and Face Pain1 citationsOpen Access

Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department

View Full Paper
GTGeneviève Tourigny‐RuelBBBenoit BaileySJSabrina Jean‐Charles

Key Points

  • To evaluate the effectiveness of intravenous dexamethasone in preventing relapse of migraines in children and adolescents treated in the emergency department.
  • Conducted a randomized controlled trial
  • Administered intravenous dexamethasone and placebo
  • Focused on children and adolescents with acute migraine attacks
  • Measured relapse rates and functional outcomes
  • Dexamethasone did not significantly reduce relapse rates compared to placebo
  • No improvement in functional outcomes observed
  • Limited findings due to low statistical power

Abstract

In this small clinical trial of children and adolescents with acute migraine attack treated in the ED, adjunctive dexamethasone did not reduce relapse rates nor improve functional outcomes compared with placebo. Although limited by low statistical power, these findings raise questions about the routine use of dexamethasone in migraine management of children and adolescents.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tourigny‐Ruel et al. (2026) studied this question.

synapsesocial.com/papers/69d34dfc9c07852e0af9799ehttps://doi.org/10.1111/head.70087
Ask AI
Helpful
Bookmark
Share
View Full Paper